Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 322 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Vancomycin hydrochloride Clear all

Conditions: Tissue Expander Based Breast Reconstruction
Interventions: Antibiotic loaded calcium sulfate beads, Polymethylmethacrylate antibiotic disc; Device
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Enterococcal Bacteremia
Interventions: Not listed
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 8
States / cities: Miami, Florida • Detroit, Michigan • Jackson, Mississippi + 4 more

Conditions: Infectious Disease
Interventions: Vancomycin; Drug
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Isolate, Linezolid
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Infection, Neutropenia, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: daptomycin, vancomycin; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Up to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Streptococcal Sepsis, Hematologic Malignancies
Interventions: Empirical Vancomycin, Prophylactic Vancomycin; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Early Stage Non-Small Cell Lung Cancer
Interventions: Vancomycin, Precision hypofractionated radiation; Drug · Radiation
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Clostridium Difficle Colitis, Clostridium Difficle Associated Disease
Interventions: Not listed
Lead sponsor: Maimonides Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Infection
Interventions: Vancomycin concentrations; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Ulcerative Colitis
Interventions: Vancomycin Pre-Treatment, Placebo for Vancomycin Pre-Treatment, SER-287, Placebo for SER-287; Drug
Lead sponsor: Seres Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 81
States / cities: Phoenix, Arizona • North Little Rock, Arkansas • La Jolla, California + 70 more

Conditions: Infection
Interventions: APPI of TKR-Stimulan; Procedure
Lead sponsor: Michael Muldoon, M.D.; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Clostridium Difficile Infection Recurrence
Interventions: FMT oral capsule, Oral Vancomycin, FMT oral placebo, Oral Vancomycin placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Chicago, Illinois • Indianapolis, Indiana • Rochester, Minnesota + 2 more

Conditions: Hepatocellular Carcinoma, Hepatocellular Cancer, Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, Liver Metastasis
Interventions: nivolumab, tadalafil, oral vancomycin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Autism Spectrum Disorder, Autism
Interventions: Fecal Microbiota Transplant; Vancomycin; Biological
Lead sponsor: ProgenaBiome; Other
Eligibility: 2 Years and older
U.S. locations: 1
States / cities: Ventura, California

Conditions: Febrile Neutropenia
Interventions: linezolid, vancomycin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 13 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 16
States / cities: Los Angeles, California • Springfield, Illinois • The Bronx, New York + 5 more

Conditions: Surgical Site Infection, Vancomycin
Interventions: Administration of Vancomycin; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 31 Days to 18 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Bacterial Pneumonia
Interventions: Telavancin, Vancomycin; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 761 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Congenital Heart Diseases, Aortic Valve Disorder
Interventions: Cefazolin 25 mg/kg body weight and Vancomycin hydrochloride, Cefazolin 30 mg/kg body weight; Drug
Lead sponsor: Stanford University; Other
Eligibility: Up to 18 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Staphylococcus Aureus
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Clostridium Difficile, Spinal Cord Injury
Interventions: Fidaxomicin 200 mg, Placebo, Vancomycin; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Wounds, Acute Wounds
Interventions: AnaSept®, NSS; Device · Other
Lead sponsor: SerenaGroup, Inc.; Network
Eligibility: 18 Years to 100 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Bacterial Infections, Wounds
Interventions: Vancomycin 1.25-1.50% in a complex gel formulation trademarked Vancogel(R), Placebo, complex gel formulation without Vancomycin; Drug
Lead sponsor: Robert S Berman MD; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2024
U.S. locations: 1
States / cities: Jupiter, Florida

Conditions: Pharmacokinetics and Pharmacodynamics
Interventions: Vancomycin (IV); Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 50 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Pneumonia, Bacterial
Interventions: tigecycline, imipenem/cilastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 3
States / cities: Louisville, Kentucky • Omaha, Nebraska • Morgantown, West Virginia

Search by objective public record fields.

Local Antibiotic Concentrations With Tissue Expanders in Breast Reconstruction

VENOUS: A Translational Study of Enterococcal Bacteremia

Loading Vancomycin Doses in the Emergency Department

Determination of Genetic Relatedness of Linezolid-resistant Vancomycin-resistant Enterococci (VRE) Surveillance Cultures

Daptomycin or Vancomycin in Treating Bacteria in the Blood in Patients With Neutropenia Caused By Chemotherapy

Trial of Prophylactic Versus Empirical Vancomycin for the Prevention of Streptococcal Sepsis After Hematopoietic Cell Transplantation

Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer

Serum Vancomycin Levels in Patients Receiving Enteral Vancomycin

The Effects of Modified Ultrafiltration on Vancomycin Levels During Cardiopulmonary Bypass in Cardiac Surgery

A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis

Use of Antibiotic Carrier in Acute Periprosthetic Infections (APPI) of Total Knee Replacements

Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients

Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

Vancomycin and Fecal Microbiota Transplant in a Single Patient With Autism Spectrum Disorder

Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection

Pharmacokinetics of Preoperative Vancomycin

Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus

Pre-operative Prophylaxis With Vancomycin and Cefazolin in Pediatric Cardiovascular Surgery Patients

The Causes and Interpretation of Low-level Resistance in Staphylococcus Aureus

Use Of Oral Fidaxomicin Vs. Oral Vancomycin For Clostridium Difficile Infection In Patients With Spinal Cord Injury

Randomized Double-Blind Controlled Clinical Trial

Effects of MRSA Bactericidal Gel To Promote Healing and Eliminate MRSA in cSSTI Vancogel(TM)

Vancomycin Dose Optimization in Obesity

Study Evaluating Safety and Efficacy of Tigecycline Versus Imipenem/Cilastatin Subjects With Hospital-Acquired Pneumonia